Project description:Transcriptome analysis was performed on the rhizome tissues of Atractylodes macrocephala under different treatments. The four treatments were: sterile water irrigation alone, FS root irrigation, FS and AM201 root irrigation, and FS combined with methyltobuzin (TM) root irrigation. And the differential genes between AM201 and FO groups were identified and compared, which helps to reveal the resistance mechanism of AM201 to Atractylodes macrocephala root rot disease
Project description:Ulcerative colitis (UC), a subtype of inflammatory bowel disease (IBD), is characterized by chronic and relapsing mucosal inflammation initiating in the rectum and extending upward through part or the entire colon in a continuous fashion. Currently, 5-aminosalicylic acid agents, corticosteroids, immunomodulators, and surgery are the main treatments for UC, which are limited in clinical practice due to common nonadherence, serious adverse effects and heavy financial burden. Atractylodes macrocephala Koidz. (Baizhu) has been used for improving gastrointestinal function and treating digestive disorders for thousands of years, and is currently one of the most frequently used traditional Chinese medicines for the treatment of UC. The purpose of this study was to evaluate the effect and underlying mechanism of polysaccharide from Atractylodes macrocephala Koidz. (PAMK) on UC based on a mouse model of dextran sodium sulfate (DSS)-induced colitis. To investigate the mechanism of therapeutic effect of PAMK on colitis, we performed the microarray analysis of colonic tissues in Control, DSS and DSS+PAMK groups. The results indicated that the beneficial effect of PAMK on DSS-induced colitis may rely on the regulation of the immune response.
Project description:Forward RADseq data of Compositae, Atractylodes macrocephala, A. lancea (A. chinensis), A. ovata (A. japonica), A. coreana，A. carlinoides Raw sequence reads
Project description:Atractylenolide II (AT-II), the major bioactive compound of Atractylodes macrocephala exhibits anticancer activity against many types of tumors, but the roles and the potential mechanisms in endometrial cancer remain unclear. To explore a novel therapeutic target of AT-II for the clinical therapy of endometrial cancer, the high-throughput sequence was performed.
